American Heart Association

Patients with AF and CKD face higher ischemic stroke risk, but also increased bleeding risk, complicating OAC use. DOACs, despite lacking RCT data for advanced CKD, have been approved for CKD stage 4 due to favorable pharmacokinetics. Observational studies and the XARENO study suggest DOACs like rivaroxaban may offer kidney protection benefits over VKAs, supporting their use in advanced CKD patients with AF.

Used pacemakers can be refurbished for use in low- and middle-income countries, with no significant differences in function compared to new devices up to 90 days post-implantation, according to a study presented at the American Heart Association meeting. The My Heart Your Heart program has been sending refurbished pacemakers abroad since 2010.

Hunters at risk for heart attack/stroke due to physical exertion and colder temperatures. Positive results for sotatercept in pulmonary arterial hypertension. Fixed-dose combination of obicetrapib and ezetimibe nearly halved LDL cholesterol in statin-resistant patients. TAVR tradeoffs in permanent pacemaker rates and patient-prosthesis mismatch. Better outcomes with Sapien 3 Ultra Resilia TAVR valve. Michigan cardiologist sues for whistleblower retaliation. Machine learning algorithm RF-SLAM predicts mortality and heart failure hospitalization. Dapagliflozin reduces new-onset diabetes in cardiovascular/kidney disease patients. SGLT2 inhibitors improve outcomes in hypertrophic cardiomyopathy with diabetes. GLP-1 receptor agonists show kidney and cardiovascular benefits. Cilostazol reduces in-stent restenosis risk. Bartonella quintana infection risk in solid-organ transplant recipients. Donor-specific antibodies and allograft dysfunction linked to poor prognosis in heart transplant recipients. Regenerative capacity of human cardiomyocytes minimal in heart failure unless on left ventricle support device therapy.

Scribe Therapeutics' CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies show promise in reducing LDL-C and triglyceride levels, potentially transforming treatment for cardiometabolic diseases.

Irregular sleep patterns increase risk of heart attack or stroke by 26%, regardless of sleep duration, according to a study involving 72,000 UK Biobank participants. Sleep regularity was found to be more relevant than sleep duration in modulating major adverse cardiovascular event risk.

Articles discuss ischemic stroke in young adults, risk factors, mimics, and management, including global perspectives, pediatric stroke, and cerebrovascular complications of sickle cell disease.

Nonsurgical transcatheter heart valve replacement improved outcomes in patients with severe aortic stenosis and tricuspid regurgitation, according to two clinical trials in The New England Journal of Medicine. Charles Davidson, MD, led the Northwestern Medicine enrollment site and found early TAVR surgery beneficial over clinical surveillance. The Triscend II trial showed better combined outcomes for patients undergoing transcatheter tricuspid valve replacement compared to medical therapy alone.

Acoramidis (Attruby; BridgeBio) approved by FDA for transthyretin amyloid cardiomyopathy (ATTR-CM), based on ATTRibute-CM trial results. BridgeBio committed to providing the drug free for life to trial participants, while the drug's $244,000/year price draws scrutiny. Acoramidis mimics a natural TTR gene mutation, targeting ATTR-CM's root cause, and BridgeBio plans to seek approval in Europe, Japan, and Brazil. Additionally, gene-editing therapy nexiguran ziclumeran (nex-z; Intellia Therapeutics) shows promise in early trials for ATTR-CM.

33.1% of adults eligible for GLP-1 receptor agonist treatment for weight loss were excluded from clinical trials due to conditions like depression and hypertension, highlighting the need for screening and real-world evidence in these populations.

FDA approves BridgeBio’s Attruby (acoramidis) for ATTR-CM, reducing cardiovascular death and hospitalization. Attruby, an oral TTR stabilizer, mimics T119M mutation effects, priced at $18,759/month. ATTRibute-CM phase 3 study showed significant benefits, with open-label extension confirming reductions in mortality and hospitalizations.